2022
DOI: 10.12688/aasopenres.13323.1
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of performance and implementation characteristics of rapid point of care SARS-CoV-2 antigen testing

Abstract: Background: The COVID-19 pandemic has resulted in a need for rapid identification of infectious cases. Testing barriers have prohibited adequate screening for SARS-CoV-2, resulting in significant delays in commencement of treatment and outbreak control measures. This study aimed to generate evidence on the performance and implementation characteristics of the BD Veritor™ Plus System rapid antigen test as compared to reverse transcription polymerase chain reaction (RT-PCR) for diagnosis of SARS-CoV-2 in Kenya. … Show more

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 27 publications
0
1
0
Order By: Relevance
“…However, the supply chain of rapid tests was severely limited until the end of 2020. We were subsequently able to access some platforms to evaluate in Massachusetts (Suliman et al, 2021), and in collaboration with global partners who relied more on rapid tests to expand decentralized testing in resource-constrained settings (Kawser et al, 2022;Muthamia et al, 2022). These rapid tests necessitate different parameters in our evaluation rubric since they are known to have lower sensitivities than molecular tests, but can be powerful tools for screening highly infectious individuals with high SARS-CoV-2 viral loads (Guglielmi, 2020;Ricco et al, 2022).…”
Section: Assessing Candidate Technologiesmentioning
confidence: 99%
“…However, the supply chain of rapid tests was severely limited until the end of 2020. We were subsequently able to access some platforms to evaluate in Massachusetts (Suliman et al, 2021), and in collaboration with global partners who relied more on rapid tests to expand decentralized testing in resource-constrained settings (Kawser et al, 2022;Muthamia et al, 2022). These rapid tests necessitate different parameters in our evaluation rubric since they are known to have lower sensitivities than molecular tests, but can be powerful tools for screening highly infectious individuals with high SARS-CoV-2 viral loads (Guglielmi, 2020;Ricco et al, 2022).…”
Section: Assessing Candidate Technologiesmentioning
confidence: 99%